Clinical Trial Update: Selective β2-AR Antagonism in Asthma [Phase 1]

View source ↗

Summary

Phase 1 trial update for a selective beta-2 adrenergic receptor antagonist in asthma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• β2-adrenergic receptor antagonist (trial agent)

Snippet

Sponsor: Trio Medicines Ltd. | Conditions: Asthma | Phase 1 | Status: COMPLETED